Director, Global Initiative for Psychedelic Science Economics
Elliot Marseille, DrPH, MPP
University of California, Berkeley
Dr. Marseille is a leading expert on the economics of the emerging psychedelic-assisted therapies. He is the founding Director of the UCB / UCSF Global Initiative for Psychedelic Science Economics (GIPSE), a network of health economists and health services researchers dedicated to realizing the potential of psychedelic therapies for high-priority mental health conditions. Through the application of policy-relevant economic analyses, GIPSE seeks to enhance the efficiency of service delivery, and increase access to these promising therapies. Current projects include consultation with the Multidisciplinary Association for Psychedelic Studies (MAPS) in modeling the economics of MDMA-assisted psychotherapy for the treatment of severe PTSD; with the Usona Institute in analyzing the cost-effectiveness of psilocybin-assisted therapy for major depression; and with John Hopkins University on the cost-effectiveness of psilocybin-assisted therapy for tobacco cessation. GIPSE is also collaborating with Phaneros on an analysis of changes in health care utilization in conjunction with trials of MDMA and psilocybin in Brazil. Dr. Marseille has 35 years of senior public health management and research experience and has published widely on the economics of global health diseases and conditions, with a focus on HIV/AIDS. He is the Course Director for Cost-Effectiveness Analysis in Medicine and Public Health, at UCSF. Additional interests include examination of the ethical foundations of cost-effectiveness analysis and identifying sound criteria for judging cost-effectiveness.